表紙
市場調査レポート

中国における抗血栓薬市場の分析

Research Report on China's Antithrombotic Drug Market, 2013-2017

発行 China Research and Intelligence 商品コード 257250
出版日 ページ情報 英文 40 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
中国における抗血栓薬市場の分析 Research Report on China's Antithrombotic Drug Market, 2013-2017
出版日: 2012年12月14日 ページ情報: 英文 40 Pages
概要

現時点での報告によると、中国では年間700万人以上の患者が急性の心臓−脳血栓症を患っており、このうち約半数が死亡し、生存者の約3分の2が日常生活の自立能力を一部または完全に失っています。現在の中国における抗血栓約市場規模は小さいものの、近年急速に成長しています。同市場の2006年から2012年の成長率は連続して20%を上回りました。病院で利用される抗血栓薬の市場規模は2012年に前年比21.9%で成長し、99億2,000万人民現に達しています。

当レポートでは、中国の抗血栓薬市場について分析し、中国における血栓症の発生率、病院における抗血栓薬の市況、主な抗血栓薬メーカーと競合、発展動向、予測などをまとめ、概略以下の構成でお届けします。

第1章 抗血栓薬の概要

  • 血栓症の概要
  • 世界の抗血栓薬の概要
    • 抗血栓薬の分類
    • 抗凝血剤
    • 血小板凝集阻害薬
    • 血栓溶解薬
    • 抗血栓薬市場の概要

第2章 中国における抗血栓薬市場の分析

  • 病院で使用される抗血栓薬の市場規模
  • 病院で使用される各種抗血栓薬のシェア
  • 病院で使用される抗血栓薬の市場シェア
  • 病院で使用される各種抗血栓薬の市場成長率

第3章 中国市場における主な抗血栓薬の分析

  • ヘパリン薬
  • ルンブロキナーゼ
  • ウロキナーゼ
  • オザグレルナトリウム・クロピドグレル
  • Rivaroxaban
  • シロスタゾール
  • アルテプラーゼ
  • 没食子酸プロピル

第4章 中国における主な抗血栓薬の価格:参考

第5章 抗血栓薬の発展予測

  • 市場規模予測
  • 技術動向

図表

目次

Thrombosis refers to the formation of local blood clots. Among it, artery thrombosis can cause myocardial infarction, stroke, acute coronary syndrome, peripheral arterial diseases, etc.; venous thrombosis can cause pulmonary embolism. Arteriovenous thrombosis is the primary reason for incidence and death of cardiovascular diseases, which is also one of the important causes for death of cancer patients.

Nowadays, cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) are severely threatening the life and health of the elderly worldwide. Cardiac-cerebral thrombotic diseases are called as the No.1 killer of the life and health of human beings currently. Cardiac-cerebral thrombotic diseases are characterized by high incidence rate, mortality rate and disability rate as well as suddenness. Since the reform and opening up, because of the continuous improvement in people's living standards as well as the rise in aging trend, the incidence rate of cardiac-cerebral thrombotic diseases continuously rises in China. According to statistics, the proportion of people dying from cardiac-cerebral thrombotic diseases already exceeds 70% in the dead aged above 60 in China's large cities. At present, the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients tend to be increasingly young.

It is reported that at present, over 7 million patients suffer from acute cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) in China annually. Among them, nearly half of the patients die; in survival patients, nearly two-thirds of them are maimed or completely lose self-care ability of daily living. Cardiac-cerebral thrombotic diseases cause not only pain to patients but also huge economic burdens to their families.

Antithrombotic drugs are used for the prevention and treatment of thromboembolic diseases, with the emphasis on prevention. Clinically, they are mainly used for the treatment and prevention of acute myocardial infarction and stroke embolism, which can reduce rates of re-infarction and mortality; they can be used for the prevention of heart valve replacement surgery postoperative thrombosis and the treatment of occlusive peripheral vascular diseases, intermittent claudication, unstable angina pectoris, etc. At present, the fast-growing indication is the prevention of deep vein thrombosis after orthopedic surgeries (such as knee and hip replacement surgeries as well as abdominal surgery).

Antithrombotic drugs are divided into anticoagulants, anti-platelet aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The market growth rate was consecutively over 20% from 2006 to 2012. The market size of hospital-use antithrombotic drugs reaches CNY 9.92 billion in 2012, with an increase of 21.9% YOY.

As the population further aging in China, on one hand, the incidence rate of vascular embolic diseases rises year by year; on the other hand, surgeries such as the interventional treatment of cardiovascular and cerebrovascular rapidly develop. The synchronous follow-up of anti-freezing, anti-platelet and lowering the blood lipid treatment after the stent surgery, promotes the capacity expansion of China's antithrombotic drug market. The market size of China's hospital-use antithrombotic drugs is expected to be over CNY 20 billion in 2017.

More following information can be acquired through this report:

  • Incidence of Thrombosis in China
  • Market Situation of China's Antithrombotic Drugs in Hospitals
  • China's Major Antithrombotic Drug Manufacturers and Competition
  • Development Trend of Antithrombotic Drugs in China
  • Following people are recommended to buy this report:
  • Antithrombotic Drug Manufacturers
  • Pharmaceutical Trade Enterprises
  • Hospitals
  • Investors/Research Institutions Focusing on Pharmaceutical Industry

Table of Contents

1. Overview on Antithrombotic Drugs

  • 1.1. Overview on Thrombosis
  • 1.2. Overview on Global Antithrombotic Drugs
    • 1.2.1. Classification of Antithrombotic Drugs
    • 1.2.2. Anticoagulants
    • 1.2.3. Anti-platelet Aggregation Drugs
    • 1.2.4. Thrombolytic Drugs
    • 1.2.5. Overview on Antithrombotic Drug Market

2. Analysis on China's Antithrombotic Drug Market, 2007-2012

  • 2.1. Market Size of Hospital-use Antithrombotic Drugs
  • 2.2. Market Share of Hospital-use Various Antithrombotic Drugs
  • 2.3. Market Share of Hospital-use Antithrombotic Drugs
  • 2.4. Market Growth Rates of Various Hospital-use Antithrombotic Drugs

3. Analysis on Major Varieties of Antithrombotic Drugs in China's Market

  • 3.1. Heparin Drugs
  • 3.2. Lumbrokinase
  • 3.3. Urokinase
  • 3.4. Sodium Ozagrel and Clopidogrel
    • 3.4.1. Sodium Ozagrel
    • 3.4.2. Clopidogrel
  • 3.5. Rivaroxaban
  • 3.6. Cilostazol
  • 3.7. Alteplase
  • 3.8. Propyl Gallate

4. Prices of China's Major Antithrombotic Drugs for Reference, 2012

5. Prediction on Development of Antithrombotic Drugs

  • 5.1. Prediction on Market Size
  • 5.2. Technology Trend

Selected Charts

  • Chart Market Size of Global Platelet Aggregation Inhibitors, 2007-2011
  • Chart Antithrombotic Drugs in the Top 50 Bestselling Drugs Globally, 2011
  • Chart Market Size of China's Antithrombotic Drugs in Hospitals, 2007-2012
  • Chart Market Shares of Major Varieties of China's Antithrombotic Drugs in Hospitals, 2007-2011
  • Chart Top 20 Antithrombotic Drug Manufacturers in China's Hospital Market, 2007-2011
  • Chart Market Share of China's Low Molecular Weight Heparin Sodium Enterprises in Hospital Drugs, 2010-2011
  • Chart Specifications and Reference Prices of Major Antithrombotic Drugs in China's Market, 2012
  • Chart Market Share of China's Alteplase Enterprises in Hospital Drugs, 2010-2011
  • Chart Prediction on Market Size of China's Antithrombotic Drugs in Hospitals, 2013-2017
Back to Top